OSWG recommendations for genotoxicity testing of novel oligonucleotide-based therapeutics

Nucleic Acid Therapeutics

Volumn 26, Issue 2, 2016, Pages 73-85

  Berman, Cindy L ^a   Barros, Scott A ^b   Galloway, Sheila M ^c   Kasper, Peter ^d   Oleson, Frederick B ^e   Priestley, Catherine C ^f   Sweder, Kevin S ^g   Schlosser, Michael J ^h   Sobol, Zhanna ⁱ  

^a Berman Consulting   (United States)

^b ALNYLAM PHARMACEUTICALS   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d Federal Institute for Drugs and Medical Devices   (Germany)

^e Research Consultant   (United States)

^f ASTRAZENECA   (United Kingdom)

^g SYRACUSE UNIVERSITY   (United States)

^h MSR Pharma Services   (United States)

ⁱ PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; OLIGONUCLEOTIDE;

ARTICLE; CHEMICAL MODIFICATION; DNA REPAIR; DNA REPLICATION; GENE MUTATION; GENOTOXICITY; GENOTOXICITY ASSAY; HUMAN; IN VITRO STUDY; MAMMAL CELL; PRIORITY JOURNAL; SEQUENCE ANALYSIS; TOXICITY TESTING; TRIPLE HELIX; ANIMAL; CELL CULTURE; DNA DAMAGE; MUTAGEN TESTING; PRECLINICAL STUDY;

ANIMALS; CELLS, CULTURED; DNA DAMAGE; DRUG EVALUATION, PRECLINICAL; HUMANS; MUTAGENICITY TESTS; OLIGONUCLEOTIDES;

EID: 84964411845     PISSN: 21593337     EISSN: 21593345     Source Type: Journal    
DOI: 10.1089/nat.2015.0534     Document Type: Article

References (69)

1. Schubert D, AA Levin, D Kornbrust, CL Berman, J Cavagnaro, S Henry, R Seguin, N Ferrari and SB Shrewsbury. (2012). The Oligonucleotide SafetyWorking Group (OSWG). Nucleic Acid Ther 22: 211-212
2. ICH S6(R1). (1997. Addendum added 2011). Preclinical safety evaluation of biotechnology-derived pharmaceuticals
3. Lee S-L, P Brown, J Wang and RT Dorsam. (2013). Nonclinical safety assessments and clinical pharmacokinetics for oligonucleotides therapeutics: a regulatory perspective. In: Advanced Delivery and Therapeutic Applications of RNAi. Cheng K, RI Mahato, eds. John Wiley and Sons, Ltd., Chichester, United Kingdom, pp 63-81
4. EMEA. (2005). CHMP SWP Reflection paper on the assessment of the genotoxic potential of antisense oligodeoxynucleotides. Doc. Ref.EMEA/CHMP/SWP/199726/2004 www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003149.pdf
5. ICH S2A. (1996). Specific aspects of regulatory genotoxicity tests for pharmaceuticals. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm074925.pdf
6. ICH S2B. (1997). Genotoxicity: a standard battery for genotoxicity testing of pharmaceuticals. www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm074929.pdf
7. ICH S2(R1). (2011). Guidance on genotoxicity testing and data interpretation for pharmaceuticals intended for human use. www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Safety/S2-R1/Step4/S2R1-Step4.pdf
8. Henry SP, DK Monteith, JE Matson, BH Mathison, KS Loveday, RA Winegar, JE Matson, PS Lee, ES Riccio, JP Bakke and AA Levin. (2002). Assessment of the genotoxic potential of ISIS 2302: a phosphorothioate oligodeoxynucleotide. Mutagenesis 17: 201-209
9. FDA. (2013). Center for drug evaluation and research application number 203568Origi1s000 pharmacology review(s). www.accessdata.fda.gov/drugsatfda-docs/nda/2013/203568 Orig1s000PharmR.pdf
10. Kynamro Prescribing Information. (2013, revised 3, 2015). Cambridge, MA: Genzyme Corporation
11. Sazani P, DL Weller and SB Shrewsbury. (2010). Safety pharmacology and genotoxicity evaluation of AVI-4658. Int J Toxicol 29: 143-156
12. Ponstein-Samarro Doorten AY and SJ De Kimpe. (2011). Absence of genotoxicity by antisense oligonucleotide PRO044. American College of Toxicology 32nd Annual Meeting Poster #P411
13. Ponstein-Samarro Doorten AY, C Den Besten and S De Kimpe. (2013). Absence of genotoxicity in a series of 2¢O-methyl phosphorothioate oligonucleotides. Society of Toxicology 52nd Annual Meeting Poster #556
14. Food and Drug Administration. (2004). Center for Drug Evaluation and Research Application Number 21-756 Pharmacology Review(s). www.accessdata.fda.gov/drugsatfda-docs/nda/2004/21-756-Macugen-pharmr.pdf
15. EMEA. (2006). Scientific Discussion for Macugen (pegaptanib).www.ema.europa.eu/docs/en-GB/document-library/EPAR---Scientific-Discussion/human/000620/WC500026218.pdf
16. Shen W, XH Liang, H Sun and S Crooke. (2015). 2¢-Fluoromodified phosphorothioate oligonucleotide can cause rapid degradation of P54nrb and PSF. Nucleic Acids Res 43: 4569-4578
17. Fruijtier-Pölloth C. (2005). Safety assessment on polyethylene glycols (PEGs) and their derivatives as used in cosmetic products. Toxicology 214: 1-38
18. Nakai D, T Seita, T Terasaki, S Iwasa, Y Shoji, Y Mizushima and Y Sugiyama. (1996). Cellular uptake mechanism for oligonucleotides: involvement of endocytosis in the uptake of phosphodiester oligonucleotides by a human colorectal adenocarcinoma cell line, HCT-15. J Pharmacol Exp Ther 278: 1362-1372
19. Bennett CF, MY Chiang, H Chan, JE Shoemaker and CK Mirabelli. (1992). Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol Pharmacol 41: 1023-1033
20. Koller E, TM Vincent, A Chappell, S De, M Manoharan and CF Bennett. (2011). Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes. Nucleic Acids Res 39: 4795-4807
21. Younis HS, T Machemer, DA Norris, S Burel and SP Henry. (2013). Evaluation of antisense oligonucleotides in human PBMCs and association of release of IL-6 in vitro to constitutional symptoms. The Toxicologist 132(1), AB# 1816
22. Pei Y, PJ Hancock, H Zhang, R Bartz, C Cherrin, N Innocent, CJ Pomerantz, J Seitzer, Koser ML, et al. (2010). Quantitative evaluation of siRNA delivery in vivo. RNA 16: 2553-2563
23. Basha G, TI Novobrantseva, N Rosin, YY Tam, IM Hafez, MK Wong, T Sugo, VM Ruda, J Qin, et al. (2011). Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells. Mol Ther 19: 2186-2200
24. Yang XZ, S Dou, TM Sun, CQ Mao, HX Wang and J Wang. (2011). Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy. J Control Release 156: 203-211
25. Wang X, B Yu, Y Wu, RJ Lee and LJ Lee. (2011). Efficient down-regulation of CDK4 by novel lipid nanoparticlemediated siRNA delivery. Anticancer Res 31: 1619-1626
26. Macugen Prescribing Information. (2011). San Dimas, CA: Gilead Science, Inc.
27. Glover JM, JM Leeds, TGK Mant, D Amin, DL Kidner, JE Zuckerman, RS Geary, AA Levin and WR Shanahan Jr. (1997). Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligonucleotide (ISIS 2302). J Pharmacol Exp Ther 282: 1173-1180
28. Geary RS, JM Leeds, J Fitchett, T Burckin, L Truong, C Spainhour, M Creek and AA Levin. (1997). Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression. Drug Metab Dispos 25: 1272-1281
29. Wei X, G Dai, Z Liu, H Cheng, Z Xie, G Marcucci and KK Chen. (2006). Metabolism of GTI-2040, a phosphorothioate oligonucleotide antisense, using ion-pair reversed phase high performance liquid chromatography (HPLC) coupled with electrospray ion-trap mass spectroscopy. AAPS J 8: E743-E755
30. Gilar A, A Belenky, DL Smisek, A Bourque and AS Cohen. (1997). Kinetics of phosphorothioate oligonucleotide metabolism in biological fluids. Nucleic Acids Res 25: 2615-2620
31. Kunz BA, SE Kohalmi, TA Kunkel, CK Mathews, EM McIntosh and JA Reidy. (1994). International commission for protection against environmental mutagens and carcinogens report. Deoxyribonucleoside triphosphate levels: a critical factor in the maintenance of genetic stability. Mutat Res 318: 1-64
32. Mathews CK. (2006). DNA precursor metabolism and genomic stability. FASEB J 20: 1300-1314
33. Richardson FC, BC Tennant, DJ Meyer, KA Richardson, PC Mann, GR McGinty, JL Wolf, PM Zack and RA Bendele. (1999). An evaluation of the toxicities of 2¢fluorouridine and 2¢fluorocytidine-HCl in F344 rats and woodchucks (Marmota monax). Toxicol Pathol 27: 607-617
34. Richardson FC, C Zhang, SR Lehrman, H Koc, JA Swenbrug, KA Richardson and RA Bendele. (2002). Quantification of 2¢fluoro-2¢deoxyuridine and 2¢fluoro- 2¢deoxycytidine in DNA and RNA isolated from rats and woodchucks using LC/MS/MS. Chem Res Toxicol 15: 922-926
35. Richardson FC, RD Kuchta, A Mazurkiewicz and KA Richardson. (2000). Polymerization of 2¢-fluoro and 2¢Omethyl- dNTPs by human DNA polymerase a, polymerase g, and primase. Biochem Pharmacol 59: 1045-1052
36. Wutzler P and R Thust. (2001). Genetic risks of antiviral nucleoside analogues-A survey. Antiviral Res 49: 55-74
37. Negishi K, T Bessho and H Hayatsu. (1994). Nucleoside and nucleobase analog mutagens. Mutat Res 318: 227-238
38. Wright GE and NC Brown. (1990). Deoxyribonucleotide analogs as inhibitors and substrates of DNA polymerases. Pharmacol Ther 47: 447-497
39. Reshat R, CC Priestley and NG Gooderham. (2012a). Mutagenesis by an antisense oligonucleotide and its degradation product. Toxicol Sci 130: 319-327
40. Caldecott KW. (2014). Ribose- an internal threat to DNA. Science 343: 260-261
41. Wang G, MM Seidman and PM Glazer. (1996). Mutagenesis in mammalian cells induced by triple helix formation and transcription-coupled repair. Science 271: 802-805
42. Ames BN, FD Lee and WE Durston. (1973). An improved bacterial test system for detection and classification of mutagens and carcinogens. Proc Nat Acad Sci U S A 70: 782-786
43. Chen I and D Dabnau. (2004). DNA uptake during bacterial transformation. Nat Rev Microbiol 2: 241-249
44. Overballe-Petersen S, K Harms, LAA Orlando, JVM Mayar, S Rasmussen, TW Dahl, MT Rosing, AM Poole, T Sicheritz-Ponten, et al. (2013). Bacterial natural transformation by highly fragmented and damaged DNA. Proc Natl Acad Sci U S A 110: 18960-18965
45. Sinha S and RJ Redfield. (2012). Natural DNA uptake by Escherichia coli. PLoS One 7: e35620
46. Sandrini MP, AR Clausen, SL On, FM Aarestrup, B Munch- Petersen and J Piskur. (2007). Nucleoside analogues are activated by bacterial deoxyribonucleoside kinases in a species-specific manner. J Antimicrob Chemother 60: 510-520
47. Kirby PE, AM Back and FB Oleson. (1985). L5178Y tk-mouse lymphoma assay of FIAU, a nucleoside analogue: a false positive response. Environ Mutagen 7: 9-10
48. Saleh AF, C Priestley, NJ Gooderham and M Fellows. (2015). Re-evaluation of the mutagenic response to phosphorothioate nucleotides in human lymphoblastoid TK6 cells. Toxicol Sci 145: 169-176
49. Praus P, E Ko-cišová, P Mojzeš, J Š těpánek and F Sureau. (2012). Study of cellular uptake of modified oligonucleotides by using time-resolved microspectrofluorimetry and florescence imaging. Spectrosc Int J 27: 415-419
50. Felsenfeld G and A Rich. (1957). Studies on the formation of two- and three-stranded polyribonucleotides. Biochim Biophys Acta 26: 457-468
51. Felsenfeld G, DR Davies and A Rich. (1957). Formation of a three-stranded polynucleotide molecule. J Am Chem Soc 79: 2023-2024
52. Kuan JY and PM Glazer. (2004) Targeted gene modification using triplex-forming oligonucleotides. Methods Mol Biol 262: 173-194
53. Hansen ME, T Bentin and PE Nielsen. (2009). Highaffinity triplex targeting of double stranded DNA using chemically modified peptide nucleic acid oligomers. Nucleic Acids Res 37: 4498-4507
54. Beal PA and PB Dervan. (1991). Second structural motif for recognition of DNA by oligonucleotide-directed triplehelix formation. Science 251: 1360-1363
55. Seidman MM, N Puri, A Majumda, B Cuenoud, PS Miller and R Alam. (2005). The development of bioactive triple helixforming oligonucleotides. Ann N Y Acad Sci 1058: 119-127
56. Jain A, G Wang and KM Vasquez. (2008). DNA triple helices: biological consequences and therapeutic potential. Biochimie 90: 1117-1130
57. Aich P, S Ritchie, K Bonham and JS Lee. (1998). Thermodynamic and kinetic studies of the formation of triple helices between purine-rich deoxyribo-oligonucleotides and the promoter region of the human c-src protooncogene. Nucleic Acids Res 26: 4173-4177
58. Cheng AJ and MW Van Dyke. (1994). Oligodeoxyribonucleotide length and sequence effects on intermolecular purine-purine-pyrimidine triple-helix formation. Nucleic Acids Res 22: 4742-4747
59. Cheng YK and BM Pettit. (1992). Stabilities of double- and triple-strand helical nucleic acids. Prog Biophys Mol Biol 58: 225-257
60. Gowers DM and KR Fox. (1997). DNA triple helix formation at oligopurine sites containing multiple contiguous pyrimidines. Nucleic Acids Res 25: 3787-3794
61. Orson FM, J Klysik, De Bergstrom, B Ward, GA Glass, P Hua and BM Kinsey. (1999). Triple helix formation: binding avidity of acridine-conjugated AG motif third strands containing natural, modified and surrogate bases opposed to pyrimidine interruptions in a polypurine target. Nucleic Acids Res 27: 810-816
62. Vasquez KM, JM Dagle, DL Weeks and PM Glazer. (2001). Chromosome targeting at short polypurine sites by cationic triplex-forming oligonucleotides. J Biol Chem 276: 38536-38541
63. Vasquez KM, L Narayanan and PM Glazer. (2000). Specific mutations induced by triplex-forming oligonucleotides in mice. Science 290: 530-533
64. Chin JY, EB Schleifman and PM Glazer. (2007). Repair and recombination induced by triple helix DNA. Front Biosci 12: 4288-4297
65. Vasquez KM, G Wang, PA Havre and PM Glazer. (1999). Chromosomal mutations induced by triplex-forming oligonucleotides in mammalian cells. Nucleic Acids Res 27: 1176-1181
66. Hegan DS, L Narayanan, FR Jirik, W Edelmann, RM Liskay and PM Glazer. (2006). Differing patterns of genetic instability in mice deficient in the mismatch repair genes Pms2, Mlh1, Msh2, Msh3, and Msh6. Carcinogenesis 27: 2402-2408
67. Reshat R, CC Priestley and NG Gooderham. (2012). A triple-helix forming oligonucleotide targeting genomic DNA fails to induce mutation. Mutagenesis 27: 713-719
68. Ashby J and D Paton. (1993). The influence of chemical structure on the extent and sites of carcinogenesis of 522 rodent carcinogens and 55 different human carcinogen exposures. Mutat Res 286: 3-74
69. ICH (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use) M7. (2014). Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk, step 4 www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Multidisciplinary/M7/M7-Step-4.pdf